

Best of 2024 SABCS® Bulgaria

February 14 – 15, 2025
hybrid format

Sofia, hotel *Millennium*, hall *Mozart*

PROGRAMA

February 14, 2025

10:00 – 18:00 *Registration*

14:00 – 14:10 Official opening

14:10 – 14:40 Voice of the Patient: Organization in the Pathway of the Patient with Breast Cancer in Bulgaria
Gergana Bogdanova (One of 8), Dr. Stanimir Kacheshmarov (GP), Assoc. Prof. Dr. Assia Konsoulova (BJCN)

14:45 – 15:30 *Symposium, supported by the industry – Novartis*

When, how and how much in breast cancer

Moderator: *Assoc. Prof. Dr. Dimitar Kalev*

Multidisciplinary scientific discussion panel:

- Assessment of the risk of recurrence in early breast cancer
- Modern guidelines in breast cancer staging
- The role of some additional factors

Panelists: *Assoc. Prof. Dr. Assia Konsoulova, Dr. Vanya Mitova, Dr. Margarita Taushanova*

15:35 – 16:40 **SABCS® 2024 Module 1**

Moderator: *Prof. Dr. Savelina Popovska*

15:35 – 15:50 Genomic prediction in early and metastatic breast cancer
Lyubomir Balabanski

15:50 – 16:05 Biomarkers in early breast cancer
Prof. Dr. Savelina Popovska

16:05 – 16:25 Immuno-oncology in early breast cancer
Assoc. Prof. Dr. Zhelyazko Arabadzhiev

16:25 – 16:40 Debate: High-risk early breast cancer should be routinely screened for recurrence using ctDNA, TILs and other markers
Prof. Dr. Savelina Popovska, Assoc. Prof. Dr. Zhelyazko Arabadzhiev, Lyubomir Balabanski

16:40 – 17:10 *Coffe braek*

17:10 – 17:40 **SABCS® 2024 Модул 2**
Moderator: *Assoc. Prof. Dr. Assia Konsoulova*

17:10 – 17:30 Indicators and interventions for monitoring breast cancer
Dr. Dimo Manov

17:30 – 17:40 Debate: Body weight parameters should be monitored in breast cancer survivors
Assoc. Prof. Dr. Assia Konsoulova, Dr. Dimo Manov

17:45 – 18:45 **Symposium, supported by the industry – MSD**

Modern multidisciplinary approach to the treatment of breast cancer.

Moderator: *Assoc. Prof. Dr. Assia Konsoulova*

- News from San Antonio on early stages of breast cancer
Dr. Dimo Manov
- How the behavior of the surgeon is changing in the diagnostic and treatment approach in triple negative breast cancer
Dr. Vulkan Ivanov

19:00 **Dinner**

February 15, 2025

08:00 – 16:00 **Registration**

09:00 – 10:00 **SABCS® 2024 Module 3**
Moderator: *Assoc. Prof. Dr. Assia Konsoulova*

09:00 – 09:15 Image-derived AI-based prognostic models and axillary ultrasound
Dr. Viktor Yordanov

09:15 – 09:45 Surgical axillary staging of early breast cancer
Dr. Valkan Ivanov

09:45 – 10:00 Debate: In every early breast cancer, criteria should be defined for possible avoidance of surgical axillary staging
Assoc. Prof. Dr. Assia Konsoulova, Dr. Valkan Ivanov, Dr. Viktor Yordanov

10:05 – 10:50 **Symposium, supported by the industry – AstraZeneca**

A Step Forward in the Treatment of Breast Cancer – What We Learned from the San Antonio Breast Cancer Symposium

Moderator: *Assoc. Prof. Dr. Assia Konsoulova*

- A Step Forward in Early gBRCAm Breast Cancer
Dr. Margarita Taushanova
- The Next Step in the Treatment of Advanced Breast Cancer
Dr. Bozhidara Kostova

10:50 – 11:10 **Coffe braek**

11:10 – 12:05 **SABCS® 2024 Модул 4**
Moderator: *Assoc. Prof. Dr. Assia Konsoulova*

11:10 – 11:50 Risk/biomarker-based systemic therapy in early breast cancer
Dr. Dimo Manov

11:50 – 12:05 Debate: In every early HR+/HER2– breast cancer, a genomic risk assessment should be performed to refine the perioperative therapy
Assoc. Prof. Dr. Assia Konsoulova, Dr. Dimo Manov

12:10 – 12:55 **Symposium, supported by the industry – Swixx BioPharma**

Shaping the Future: What Are the Prospects for Antibody-Drug Conjugates

- Current Principles of Treatment and the Place of Antibody- Drug Conjugates
Dr. Tsvetan Yordanov
- The Future of Antibody-Drug Conjugates
Dr. Petya Balikova

13:00 – 14:00 **Lunch**

14:00 – 14:55 **SABCS® 2024 Module 5**
Moderator: *Assoc. Prof. Dr. Assia Konsoulova*

14:00 – 14:40 Risk-based radiotherapy in early breast cancer
Dr. Dorotea Ivanova

14:40 – 14:55 Debate: The degree of risk should be considered for personalization of radiotherapy strategies in DCIS and early luminal breast cancer
Assoc. Prof. Dr. Assia Konsoulova, Dr. Dorotea Ivanova

15:00 – 15:25 **Symposium, supported by the industry – Pfizer**

Results from the largest comparative analysis of the three CDK4/6- inhibitors P-VERIFY and other highlights from SABCS 2024
Assoc. Prof. Dr. Assia Konsoulova

15:30 – 15:55 **Symposium, supported by the industry – Eli Lilly**

Therapeutic approach in patients with hormone-positive, HER2-negative early breast cancer at high risk

Real-world experience in the therapy of patients with HR+/HER2– early breast cancer at high risk of recurrence
Dr. Margarita Tauschanova

16:00 – 16:30 **Coffe braek**

16:30 – 17:25 **SABCS® 2024 Module 6**
Moderator: *Assoc. Prof. Dr. Assia Konsoulova*

16:30 – 17:10 New targeted strategies for systemic therapy in metastatic breast cancer
Dr. Petya Balikova

17:10 – 17:25 Debate: Are there limits to co-targeting in co-positive metastatic breast cancer
Assoc. Prof. Dr. Assia Konsoulova, Dr. Petya Balikova

17:30 – 18:00 **Expert opinion of the Bulgarian Joint Cancer Network:**
Changes in clinical practice from Monday
Assoc. Prof. Dr. Assia Konsoulova

18:00 – 18:10 Official closing

18:30 *Dinner*